Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionise the treatment of one of the leading causes of blindness in the UK.
The results of the collaborative research, published today in Investigative Opthamology and Visual Science, could spell the end of painful injections directly into the eye to treat the increasingly common eye disorder known as age-related macular degeneration (AMD).
AMD affects more than 600,000 people in the UK and predictions suggest this figure could rise sharply in future because of an ageing population.
A painless condition which causes people to gradually lose their central vision, usually in both eyes, AMD is currently treated by repeated injections into the eye on a monthly basis over at least three years.
This is a problem because, apart from being an unpleasant procedure for patients to undergo, the injections can cause tearing and infections inside the eye and an increased risk of blindness.
Now scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Inflammation and Ageing, have invented a method of delivering the injected drug as an eye drop instead, and their laboratory research has obtained the same outcomes as the injected drug.
The drop uses a cell-penetrating peptide (CPP) to deliver the drug to the relevant part of the eye within minutes.
Dr de Cogan said: “The CPP-drug has the potential to have a significant impact on the treatment of AMD by revolutionising drug-delivery options.
“Efficacious self-administered drug application by eye drop would lead to a significant reduction in adverse outcomes and health care costs compared with current treatments.
“The CPP-plus drug complex also has potential application to other chronic ocular diseases that require drug delivery to the posterior chamber of the eye.
“We believe this is going to be very important in terms of empowering of patients and reducing the cost of treatment to the NHS.”
The Latest on: Age-related macular degeneration
- BIOPHYTIS Strengthens its Senior Management Team and Continues its Expansion in the United States on December 16, 2018 at 9:30 pm
and MACUNEOS through our MACA study program in dry age-related macular degeneration (AMD)." Mr. Schneiderman stated: "I am thrilled to join the leadership team at BIOPHYTIS at such an exciting stage i... […]
- Edmonton to Host Clinical Trial for Nova Oculus Medical Device that Could Help Improve Vision for AMD Sufferers on December 14, 2018 at 9:00 am
AGE-RELATED Macular Degeneration has no cure. It is the No. 1 cause of severe vision loss and legal blindness in adults over 60 in North America. More than 15 million North Americans suffer from ... […]
- NuEyes Technologies Partners With Pico Interactive for Next Generation of Wearables for the Visually Impaired on December 13, 2018 at 5:57 am
Early age-related macular degeneration affects an estimated eight million Americans, of which more than one million will develop advanced age-related macular degeneration within the next five years. T... […]
- Read the bottom line: Eye doctors, Independent Health clash over drug costs on December 13, 2018 at 5:02 am
For some patients, out-of-pocket on these drugs is 20 percent of the costs." Age-related macular degeneration is a chronic, progressive disease most common in those over age 50. A dry form often ... […]
- New blood test offers hope to macular degeneration sufferers on December 13, 2018 at 12:00 am
Stirling Caldwell struggles to see the detail in his surroundings. He has age-related macular degeneration, a problem that has worsened over the past 16 years. Everything the 74-year-old sees is disto... […]
via Google News and Bing News